Ann Hanham
CIK 1286338 · last filed 2025-06-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ECYT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
13TH FLOOR
JERSEY CITY, NJ 07302
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SCYX | Director | 8,703 | $3.89 | $33.9K | $35.4K | 19 | 2025-06-30 |
| HTG MOLECULAR DIAGNOSTICS, INC (HTGM) Delisted | Director | 41 | $0.48 | $20 | $0 | 8 | 2022-09-15 |
| ENDOCYTE INC (ECYT) Delisted | Director | 62,096 | — | — | -$5.37M | 17 | 2017-05-05 |
Recent Filings · Page 4 of 5
44 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-06-21 | ENDOCYTE INC (ECYT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-05-29 | ENDOCYTE INC (ECYT) Delisted | Sell (S) | −9,900 | -$139.6K | EDGAR |
| 2013-05-22 | ENDOCYTE INC (ECYT) Delisted | Sell (S) | −40,000 | -$575.1K | EDGAR |
| 2013-05-20 | ENDOCYTE INC (ECYT) Delisted | Sell (S) | −37,200 | -$536.1K | EDGAR |
| 2013-05-16 | ENDOCYTE INC (ECYT) Delisted | Sell (S) | −40,200 | -$590.4K | EDGAR |
| 2012-06-07 | ENDOCYTE INC (ECYT) Delisted | Sell (S) | −325,100 | -$2.15M | EDGAR |
| 2012-06-04 | ENDOCYTE INC (ECYT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-04 | ENDOCYTE INC (ECYT) Delisted | Sell (S) | −27,900 | -$185.6K | EDGAR |
| 2012-05-18 | ENDOCYTE INC (ECYT) Delisted | Sell (S) | −27,900 | -$185.6K | EDGAR |
| 2012-05-16 | ENDOCYTE INC (ECYT) Delisted | Sell (S) | −147,000 | -$1.01M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.